We are live on ! Find out more
GILD icon

Gilead Sciences

1,504 hedge funds and large institutions have $81.5B invested in Gilead Sciences in 2017 Q3 according to their latest regulatory filings, with 123 funds opening new positions, 601 increasing their positions, 613 reducing their positions, and 124 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $69.4B → $81.5B (+$12.2B)

8% more funds holding in top 10

Funds holding in top 10: 8996 (+7)

2.03% more ownership

Funds ownership: 74.96%76.99% (+2%)

1% less first-time investments, than exits

New positions opened: 123 | Existing positions closed: 124

2% less repeat investments, than reductions

Existing positions increased: 601 | Existing positions reduced: 613

1% less funds holding

Funds holding: 1,5201,504 (-16)

28% less call options, than puts

Call options by funds: $1.87B | Put options by funds: $2.61B

Holders
1,504
Holders Change
-16
Holders Change %
-1.05%
% of All Funds
37.49%
Holding in Top 10
96
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+7.87%
% of All Funds
2.39%
New
123
Increased
601
Reduced
613
Closed
124
Calls
$1.87B
Puts
$2.61B
Net Calls
-$732M
Net Calls Change
-$83M
Name Holding Trade Value Shares
Change
Change in
Stake
TAM
551
Trillium Asset Management
Massachusetts
$5M -$84.6K -1,107 -2%
MAM
552
Martingale Asset Management
Massachusetts
$4.99M -$53.3K -697 -1%
FIM
553
Frontier Investment Management
Texas
$4.97M -$80.7K -1,055 -2%
HC
554
Hampstead Capital
United Kingdom
$4.94M
SCM
555
Sterneck Capital Management
Missouri
$4.9M -$419K -5,473 -8%
HFS
556
HL Financial Services
Kentucky
$4.85M -$35K -458 -0.8%
First Eagle Investment Management
557
First Eagle Investment Management
New York
$4.84M
CGI
558
CI Global Investments
California
$4.83M +$4.56M +59,658 New
CIP
559
Chartwell Investment Partners
Pennsylvania
$4.8M
CFB
560
Cullen/Frost Bankers
Texas
$4.79M -$670K -8,757 -13%
CIC
561
Cornercap Investment Counsel
Georgia
$4.77M +$264K +3,455 +6%
SIA
562
Sit Investment Associates
Minnesota
$4.71M
VCM
563
Vision Capital Management
Oregon
$4.71M -$146K -1,912 -3%
CL
564
Croft-Leominster
Maryland
$4.68M -$72.2K -944 -2%
NCM
565
Neumann Capital Management
California
$4.66M -$519K -6,785 -11%
JAM
566
Jolley Asset Management
North Carolina
$4.65M -$269K -3,512 -6%
V
567
Veritable
Delaware
$4.58M +$76.3K +998 +2%
MYAM
568
Meiji Yasuda Asset Management
Japan
$4.57M +$31.4K +410 +0.7%
SFFS
569
Stonehage Fleming Financial Services
Jersey
$4.52M +$798K +10,430 +23%
MCM
570
Monarch Capital Management
Indiana
$4.5M +$304K +3,975 +8%
RC
571
RegentAtlantic Capital
New Jersey
$4.45M +$131K +1,713 +3%
KWILP
572
Kiwi Wealth Investments Limited Partnership
New Zealand
$4.45M +$174K +2,269 +4%
CRC
573
Curi RMB Capital
Illinois
$4.41M +$2.66M +34,724 +176%
LMGAM
574
Liberty Mutual Group Asset Management
Massachusetts
$4.4M -$2.26M -29,554 -35%
EWM
575
Evercore Wealth Management
New York
$4.36M -$372K -4,866 -8%

GILD Hedge Fund Activity: Q3 2017 in Review

1,504 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2017, worth a combined $81.5B — up 18% from $69.4B a quarter earlier.

Sellers outnumbered buyers: 124 funds closed out of GILD and 123 opened new positions — a net loss of 1 holder — while 613 trimmed existing stakes and 601 added.

The largest buyer was Dodge & Cox, adding an estimated $758M. The largest seller was Susquehanna International Group, cutting an estimated $359M.

  • 1,504 institutional investors held Gilead Sciences (GILD) as of Q3 2017, down from 1,520 in Q2 2017.
  • Funds reported $81.5B of Gilead Sciences stock for Q3 2017, up 18% quarter-over-quarter.
  • 123 funds opened new Gilead Sciences positions in Q3 2017 and 124 closed out, a net change of -1 holder.
  • The largest Gilead Sciences buyer in Q3 2017 was Dodge & Cox, an estimated $758M added.
  • The largest Gilead Sciences seller in Q3 2017 was Susquehanna International Group, an estimated $359M sold.

Based on aggregated 13F filings for Q3 2017.